Focus Stocks
Sanofi-Aventis Is Near Resistance
Published on Wednesday, 30 January 2013 08:20 Written by TradersHuddle Wire
New York, January 30th (TradersHuddle.com) - Shares of Sanofi-Aventis (NYSE:SNY) are trading very close to calculated resistance at $49.28. The stock ended the trading session at just $48.80, which is near levels that make it difficult to buy or start a position.
Sanofi-Aventis (NYSE:SNY) is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.
Sanofi-Aventis' stock range is defined by its calculated support defined at $42.75 and by the resistance level at $49.28; the stock is clearly over-extended from support, making it harder for participants to establish fresh longs.
Traders don't have a clear entry point for Sanofi-Aventis . However, as the stock pulls back towards $42.75 it will definitely provide a reference point to establish a trade. On the other hand, if the stock breaks above its resistance level at $49.28 then traders will get an opportunity to enter the stock as it moves to a higher range.
Related Articles
- Critical Alerts For Sanofi, Salesforce.com, AFLAC, HCA Holdings, and Silver Wheaton Released By InvestorsObserver
- Sanofi-Aventis Is Close to the 50 Day Moving Average
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
- Approaching Resistance: Sanofi-Aventis
- Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
- Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month
- Reference Points for Sanofi-Aventis
- Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
- Approaching Resistance: Sanofi-Aventis
- Sanofi-Aventis Is Close to Resistance
Related Partner Headlines
- Sanofi Stock Buy Recommendation Reiterated (SNY) - TheStreet.com
- Sanofi (SNY): Today's Featured Drugs Laggard - TheStreet.com
- Zalicus Prednisporin Licensee Sanofi Provides Update on Development Status - Benzinga
- Sanofi Stock Buy Recommendation Reiterated (SNY) - TheStreet.com
- Sanofi Reaches New 52-Week High (SNY) - TheStreet.com
- Sanofi Stock Buy Recommendation Reiterated (SNY) - TheStreet.com
- Sanofi To Buy Genfar - Benzinga
- Sanofi Stock Buy Recommendation Reiterated (SNY) - TheStreet.com
- Sanofi (SNY): Today's Featured Health Care Laggard - TheStreet.com
- Sanofi Reaches New 52-Week High (SNY) - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,333.09 Trade time:2:45PM EDT Value change:▲25.92 (0.17%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,654.36 Trade time:2:45PM EDT Value change:▼0.99 (-0.06%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,465.76 Trade time:2:45PM EDT Value change:▲2.46 (0.07%)In The Wires
-
Destination America And USA WEEKEND Announce Winners Of The Inaugural "RED, WHITE AND YOU" Contest -
Noble Energy Announces $500,000 Donation To Support Oklahoma Relief And Recovery -
Sterling Consolidated Announces Sale of Non-Strategic Cliffwood Beach, NJ Property -
United Airlines Opens New Seattle United Club, Consolidates Operations -
Echo Therapeutics Announces Successful Unveiling of Symphony® CGM System -
BB&T declares second-quarter dividend for Series G Non-Cumulative Perpetual Preferred Stock -
Network-1 Commences Patent Litigation against Vendors of Operating System Software and Computer Systems -
PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756








